ascopubs.org3 天
Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05) Improved risk ...
ascopubs.org3 天
Misleading Reporting of a Negative Randomized Clinical Trial May Affect Clinical Practice
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org3 天
Reply to P. de Boissieu et al
View all available purchase options and get full access to this article. The sponsor was involved in the design of the study, analysis and interpretation of the data, and review of the manuscript. The ...
ascopubs.org3 天
Oncology Accelerated Approval Confirmatory Trials: When a Failed Trial Is Not a Failed Drug
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05) The following represents ...
ascopubs.org5 天
How Racialized Approaches to Opioid Use Disorder and Opioid Misuse Management Hamper ...
Correlative Science in the Cooperative Group System—Re-Engineering for Success Achieving opioid pharmacoequity or ensuring access to evidence-based pharmacologic therapies regardless of race and ...
ascopubs.org4 天
Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials ...